Neurological complications in controlled HIV infection

Current Infectious Disease Reports

Volumn 15, Issue 6, 2013, Pages 564-568

  Crossley, Kate M ^a   Brew, Bruce J ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b St Vincent's Centre for Applied Medical Research   (Australia)

Author keywords

HIV Associated Neurocognitive Disorders; Human Immunodeficiency Virus; Neurotoxicity; Peripheral Neuropathy

Indexed keywords

FLUORINE; FLUORODEOXYGLUCOSE F 18;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE INFLAMMATORY DEMYELINATING POLYNEUROPATHY; ARTICLE; ASYMPTOMATIC NEUROCOGNITIVE IMPAIRMENT; BRAIN SIZE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CEREBROVASCULAR DISEASE; CHRONIC DISEASE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEGENERATIVE DISEASE; EARLY DIAGNOSIS; GUILLAIN BARRE SYNDROME; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MILD NEUROCOGNITIVE DISORDER; MORBIDITY; NERVOUS SYSTEM INFLAMMATION; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SEIZURE; SEROCONVERSION; VIRUS LOAD; VIRUS STRAIN;

EID: 84890791620     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-013-0375-8     Document Type: Article

References (47)

1. del Palacio M, Álvarez S, Muñoz-Fernández MA. HIV-1 infection and neurocognitive impairment in the current era. Rev Med Virol. 2012;22:33-45.
2. •• Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol. 2011;17:176-83. A study of a cohort of advanced HIV+ individuals on cART that found that despite suppression of systemic viral load, HIV-related neuropsychological impairment prevalence reached 18.1%.
3. Singer EJ et al. Neurologic presentations of AIDS. Neurol Clin. 2010;28:253-75.
4. • Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol. 2011;11:148. A meta-review that found that neuroHAART improves neurocognitive function and suppresses CSF HIV RNA.
5. Mirza A, Rathore MH. Human immunodeficiency virus and the central nervous system. Semin Pediatr Neurol. 2012;19:119-23.
6. Kraft-Terry SD et al. HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis. 2010;37:542-8.
7. Peluso MJ et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26:1765-74. Retrospective case series of 10 HIV-infected patients who presented with neurological symptoms and were shown to have CSF «escape» of virus.
8. Brew BJ. Benefit or toxicity from neurologically targeted antiretroviral therapy? Clin Infect Dis. 2010;50:930-2.
9. Liner KJ, Ro MJ, Robertson KR. HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep. 2010;7:85-91.
10. • Desplats P et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology. 2013;80:1415-23. A case-control study of the neuropathologic and molecular findings in patients with latent CNS HIV-1 infection that found an association with increased levels of chromatin modifiers, including BCL11B.
11. Mocchetti I, Bachis A, Avdoshina V. Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotox Res. 2012;21:79-89.
12. Jaeger LB, Nath A. Modeling HIV-associated neurocognitive disorders in mice: new approaches in the changing face of HIV neuropathogenesis. Dis Models Mech. 2012;5:313-22.
13. Hogan C, Wilkins E. Neurological complications in HIV. Clin Med. 2011;11(6):571-5.
14. Brew BJ et al. The neurological features of early and 'latent' human immunodeficiency virus infection. Aust NZ J Med. 1989;19:700-5.
15. Antinori A, Arendt G, Becker JT. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-99.
16. Garvey L et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology. 2011;76:693-700.
17. Heaton RK et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER study. Neurology. 2010;75:2087-96.
18. • Ciccarelli N et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV infected patients. Neurology. 2011;76:1403-9. A cross-sectional single-cohort study that found an association between HAND and efavirenz use.
19. Brew BJ, et al. Neurodegeneration and ageing in the HAART Era. J Neuroimmune Pharm. 2009;4(2):163-74
20. Yao H et al. HIV neuropathogenesis: a tight rope walk of innate immunity. J Neuroimmune Pharm. 2010;5:489-95.
21. • Kallianpur KJ et al. Peripheral blood HIV DNA is associated with atrophy of cerebellar and subcortical gray matter. Neurology. 2013;80:1792-9. A cross-sectional study that used MRI and MR spectroscopy to demonstrate an association between regional brain atrophy and persistance of HIV DNA in the peripheral blood.
22. Andersen ÅB et al. Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation. 2010;7:13.
23. Gannon P, Khana MZ, Kolsona DL. Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol. 2011;24:275-83.
24. Mothobia NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis. 2012;25:4-9.
25. Johnson T, Nath A. Immune reconstitution inflammatory system and the central nervous system. Curr Opin Neurol. 2011;24:284-90.
26. Cysique LAJ, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66:1447-50.
27. Tan IL, McArthur JC. HIV-associated neurological disorders a guide to pharmacotherapy. CNS Drugs. 2012;26(2):123-34.
28. Rackstraw S. HIV-related neurocognitive impairment - a review. Psychol, Health Med. 2011;16(5):548-63.
29. Thien H et al. Improved cognitive function as a consequence of hepatitis C virus treatment. HIV Med. 2007;8:520-8.
30. McPhail ME, Robertson KR. Neurocognitive impact of antiretroviral treatment: thinking long-term. Curr HIV/AIDS Rep. 2011;8:249-56.
31. Clifford DB et al. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology. 2009;73:309-14.
32. Lindl KA et al. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharm. 2010;5:294-309.
33. • Ellisa RJ et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25:1747-51. A large observational study that showed the risk of neuropsychological impairment was lowest in patients without a low CD4 nadir pre-CART initiation.
34. Letendre SL. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med. 2011;19(4):137-42.
35. •• The Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis. 2013;56(7):1004-17. Evidence-based consensus statement from international experts to guide the diagnosis, monitoring, and treatment of HAND.
36. •• Centner CM, Bateman KJ, Heckmann JM. Manifestations of HIV infection in the peripheral nervous system. Lancet Neurol. 2013;12:295-309. A review of the clinical presentation, causes, and management of peripheral neuropathies in HIV-infected patients.
37. Ghosh S, Chandran A, Jansen JP. Epidemiology of HIV-related neuropathy: a systematic literature review. AIDS Res Hum Retrovir. 2012;28(1):36-48.
38. Kamerman PR, Wadley AL, Cherry CL. HIV-associated sensory neuropathy: risk factors and genetics. Curr Pain Headache Rep. 2012;16:226-36.
39. Ng K et al. Axonal excitability in viral polyneuropathy and nucleoside neuropathy in HIV patients. J Neurol Neurosurg Psychiatry. 2011;82:978-80.
40. Cherry CL et al. Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology. 2006;66:867-73.
41. Cruse B et al. Cerebrovascular disease in HIV-infected individuals in the era of highly active antiretroviral therapy. J Neurovirol. 2012;18:264-76.
42. Benjamin LA et al. HIV infection and stroke: current perspectives and future directions. Lancet Neurol. 2012;11:878-90.
43. Sen S et al. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovasc Dis. 2012;33:209-18.
44. Brew BJ et al. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology. 2005;65:1490-2.
45. Birbeck GL et al. Evidence-based guideline: antiepileptic drug selection for people with HIV/AIDS. Neurology. 2012;78:139-45.
46. • Heinze B, Swanepoel DW, Hofmeyr LM. Systematic review of vestibular disorders related to human immunodeficiency virus and acquired immunodeficiency syndrome. J Laryngol Otol. 2011;125:881-90. Guidelines for the selection of antiepileptic drugs among people with HIV/AIDS.
47. Brew BJ. HIV neurology. Oxford University Press; 2001.